Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Colomer

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM)R Colomer, G Viñas, M Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancerR Colomer, S Montero, A Lluch, et al.
American Journal of Human Genetics|January 1, 1993
A frequent tyrosinase gene mutation associated with type I-A (tyrosinase-negative) oculocutaneous albinism in Puerto RicoW S Oetting, C J Witkop, S A Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2001
Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cellsJ A Menéndez, M del Mar Barbacid, S Montero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 5, 2016
Advanced breast cancer clinical nursing curriculum: review and recommendationsC Vila, C Reñones, T Ferro, et al.
Seminars in Oncology|March 4, 2000
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trialR Colomer, A Llombart, A Lluch, et al.
Annals of the New York Academy of Sciences|October 27, 2010
Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancerG Oliveras, A Blancafort, A Urruticoechea, et al.
Seminars in Oncology|January 14, 1998
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancerR Hitt, L Paz-Ares, M Hidalgo, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 20, 2005
Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled cathetersA Sánchez-Muñoz, J M Aguado, A López-Martín, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 23, 2008
Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?R Colomer, R Lupu, A Papadimitropoulou, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM)R Colomer, G Viñas, M Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancerR Colomer, S Montero, A Lluch, et al.
American Journal of Human Genetics|January 1, 1993
A frequent tyrosinase gene mutation associated with type I-A (tyrosinase-negative) oculocutaneous albinism in Puerto RicoW S Oetting, C J Witkop, S A Brown, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2001
Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cellsJ A Menéndez, M del Mar Barbacid, S Montero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 5, 2016
Advanced breast cancer clinical nursing curriculum: review and recommendationsC Vila, C Reñones, T Ferro, et al.
Seminars in Oncology|March 4, 2000
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trialR Colomer, A Llombart, A Lluch, et al.
Annals of the New York Academy of Sciences|October 27, 2010
Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancerG Oliveras, A Blancafort, A Urruticoechea, et al.
Seminars in Oncology|January 14, 1998
Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancerR Hitt, L Paz-Ares, M Hidalgo, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 20, 2005
Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled cathetersA Sánchez-Muñoz, J M Aguado, A López-Martín, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 23, 2008
Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?R Colomer, R Lupu, A Papadimitropoulou, et al.
Pageof 10